DNASE1 and cystic fibrosis: Although DNase I, which could degrade cfDNA, was approved by the Food and Drug Administration (FDA) as a medicine for cystic fibrosis (CF) patients to improve pulmonary function, its clinical application is severely limited by unfavorable therapeutic effects, high costs, low stability, and side effects, such as voice changes and rash.[33] Fortunately, the biomaterials‐based anti‐inflammation strategies developed in recent years showed promise for alleviating the severe inflammatory response of patients with airway disorders.